TACR1 and stroke disorder: These findings suggest that multiple boluses of the NK1-r antagonist is a potentially viable therapeutic strategy to reduce elevated ICP following stroke, with the ability to bring about a clinically meaningful and sustainable reduction in pressure comparable to that observed in surviving patients (Hacke et al., 1996).